These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 16846546)

  • 1. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium.
    Waterbury LD; Silliman D; Jolas T
    Curr Med Res Opin; 2006 Jun; 22(6):1133-40. PubMed ID: 16846546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.
    Bucci FA; Waterbury LD
    Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation.
    Waterbury LD; Galindo D; Villanueva L; Nguyen C; Patel M; Borbridge L; Attar M; Schiffman RM; Hollander DA
    J Ocul Pharmacol Ther; 2011 Apr; 27(2):173-8. PubMed ID: 21351868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs.
    Gerstenfeld LC; Thiede M; Seibert K; Mielke C; Phippard D; Svagr B; Cullinane D; Einhorn TA
    J Orthop Res; 2003 Jul; 21(4):670-5. PubMed ID: 12798067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
    Walters T; Raizman M; Ernest P; Gayton J; Lehmann R
    J Cataract Refract Surg; 2007 Sep; 33(9):1539-45. PubMed ID: 17720067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels.
    Bucci FA; Waterbury LD
    J Cataract Refract Surg; 2008 Sep; 34(9):1509-12. PubMed ID: 18721711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ketorolac tromethamine, diclofenac sodium, and loteprednol etabonate in an animal model of ocular inflammation.
    Waterbury LD; Flach AJ
    J Ocul Pharmacol Ther; 2006 Jun; 22(3):155-9. PubMed ID: 16808675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral prostanoid levels and nonsteroidal anti-inflammatory drug analgesia: replicate clinical trials in a tissue injury model.
    Gordon SM; Brahim JS; Rowan J; Kent A; Dionne RA
    Clin Pharmacol Ther; 2002 Aug; 72(2):175-83. PubMed ID: 12189364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.
    Bucci FA; Waterbury LD
    Adv Ther; 2011 Dec; 28(12):1089-95. PubMed ID: 22105509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model.
    Higaki S; Watanabe K; Itahashi M; Shimomura Y
    Curr Eye Res; 2009 Mar; 34(3):171-6. PubMed ID: 19274523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation.
    Bucolo C; Marrazzo G; Platania CB; Romano GL; Drago F; Salomone S
    J Pharm Pharmacol; 2014 Jul; 66(7):954-60. PubMed ID: 24697218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits.
    Kida T; Kozai S; Takahashi H; Isaka M; Tokushige H; Sakamoto T
    PLoS One; 2014; 9(5):e96481. PubMed ID: 24796327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent.
    Jones J; Francis P
    Expert Opin Pharmacother; 2009 Oct; 10(14):2379-85. PubMed ID: 19735215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK).
    Durrie DS; Kennard MG; Boghossian AJ
    Adv Ther; 2007; 24(6):1278-85. PubMed ID: 18165210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat.
    Jett MF; Ramesha CS; Brown CD; Chiu S; Emmett C; Voronin T; Sun T; O'Yang C; Hunter JC; Eglen RM; Johnson RM
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1288-97. PubMed ID: 10027870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of COX-2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal.
    Brookshire HL; English RV; Nadelstein B; Weigt AK; Gift BW; Gilger BC
    Vet Ophthalmol; 2015 May; 18(3):175-85. PubMed ID: 24636042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure.
    Cappon GD; Cook JC; Hurtt ME
    Birth Defects Res B Dev Reprod Toxicol; 2003 Feb; 68(1):47-56. PubMed ID: 12852483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
    Gierse JK; Zhang Y; Hood WF; Walker MC; Trigg JS; Maziasz TJ; Koboldt CM; Muhammad JL; Zweifel BS; Masferrer JL; Isakson PC; Seibert K
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1206-12. PubMed ID: 15494548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis.
    Tanaka K; Suemasu S; Ishihara T; Tasaka Y; Arai Y; Mizushima T
    Eur J Pharmacol; 2009 Jan; 603(1-3):120-32. PubMed ID: 19101538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis.
    Miyake-Kashima M; Takano Y; Tanaka M; Satake Y; Kawakita T; Dogru M; Asano-Kato N; Fukagawa K; Fujishima H
    Jpn J Ophthalmol; 2004; 48(6):587-90. PubMed ID: 15592786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.